Physician profile
Sheldon P Blau
NPI 1376607267
$2,114.47
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,830 · 2020: $285.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $329.11 | 2019 | |
| Horizon Therapeutics Plc | $311.01 | 2019-2020 | |
| Lilly USA, LLC | $269.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $200.72 | 2019-2020 | |
| Abbvie INC. | $179.53 | 2019-2020 | |
| Janssen Biotech, INC. | $161.54 | 2019 | |
| Amgen INC. | $154.44 | 2019-2020 | |
| Pfizer INC. | $153.94 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $87.48 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $75.68 | 2019 | |
| Hikma Pharmaceuticals USA | $45.98 | 2019 | |
| Medexus Pharma, INC. | $39.42 | 2019-2020 | |
| Antares Pharma, INC. | $22.64 | 2019 | |
| Glaxosmithkline, LLC. | $19.90 | 2019 | |
| Depuy Synthes Sales INC. | $18.91 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $18.79 | 2019 | |
| Celgene Corporation | $14.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.20 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Blau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.